• PMO team

Meet our new project lead!

We are honoured to announce that Dan Baker is the new project lead of the Rheuma Tolerance for Cure project. Dan is Vice President of immunology R&D at Janssen Pharmaceutica, and he is thrilled to become part of this IMI2 project.



“I am thrilled to have the opportunity to be so closely involved in this important project that will provide solutions transformational for patients with RA and other immune based diseases.”




We say goodbye to our former project lead, Anish Suri and thank him for all the time and effort that he has put into this project. Anish has left Janssen Pharmaceutica to take up an exciting role at Cue Biopharma. He is appointed as Senior Vice President and Chief Scientific Officer of this innovative company focusing on immunotherapy. For more information about this company, you can have a look at their website: https://www.cuebiopharma.com/.


We would like to thank Anish for his support, and to welcome Dan to the team!


We wish you both good luck with your new adventures!

38 views

Recent Posts

See All

Two PRP's share about their involvement with RTCure

Tom Esterine and Ruth Williams are two Expert Patients at King’s College London, who work with Heidi Lempp in the Centre for Rheumatic Disease. With a lot of enthusiasm, they share their insight in wo

PRP Newsletter - May 2020

Following this link you can find the EULAR Patient Research Partners newsletter of May 2020. This newsletter contains an invitation to the virtual EULAR 2020 E-Congress, links to interesting articles

  • Follow us on Twitter

Follow us on Twitter:

The RTCure project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement no 777357. This joint undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and EFPIA.

The communication reflects the author's view; neither IMI nor the European Union or EFPIA  are responsible for any use that may be made of the information contained herein.